The results of a survey released on 1 March 2021 by independent pollster Levada-Centre (Levada) indicate that over 60% of Russians said they are not ready to get a shot of the Russian Sputnik V COVID-19 vaccine, CNN reported on Tuesday.
According to Levada, which conducted the poll in late February 2021 and queried 1,601 people in 50 regions via in-person interviews, 62% of Russians surveyed said they don't want to be vaccinated with Sputnik V. Only 30% said they would, as compared to 38% in December 2020.
The main reasons stated by respondents against getting the vaccine were concerns over side effects (37% of those not ready for vaccination) or wanting to wait until the trials are complete (23%).
Another 16% of respondents said they "don't see any point" in getting vaccinated. In December 2020, fewer people feared side effects (29%) and more were waiting for the trials to finish (30%).
This survey also found that 64% of people thought the theory that COVID-19 was created artificially as a biological weapon was more probable than its natural origin, which only 23% believed.
Reportedly, the origins of COVID-19 became highly politicised in 2020 and many conspiracy theories have arisen in the US, Russia and elsewhere about the origins of the virus in humans.
The World Health Organisation team that went to Wuhan, China in February 2021 to explore the origins of COVID-19 said the version that the virus emerged from a lab is highly unlikely and is not being investigated further.
GSK to receive USD370m and future royalties in CureVac/BioNTech settlement
FDA lifts pause on Valneva's chikungunya vaccine IXCHIQ for elderly, updates prescribing information
Anixa Biosciences begins US FDA approved IND transfer to support Phase 2 breast cancer vaccine trial
Pfizer and BioNTech receive EU regulatory backing for LP.8.1-adapted COVID-19 vaccine
Sanofi to acquire Vicebio for USD1.15bn to strengthen respiratory vaccine pipeline
Bavarian Nordic chikungunya vaccine enters Health Canada review process
SK bioscience submits IND for Phase 1/2 clinical trial of new influenza vaccine candidate
GC Biopharma secures Vietnamese approval for varicella vaccine BARYCELA
GSK announces submission of RSV vaccine Arexvy for FDA review
PharmaJet signs MOU with Egyptian UPA and EVA Pharma to introduce needle-free vaccine delivery
Centivax raises USD45m to commercialise universal flu vaccine
CyanVac's nasal COVID vaccine shows promise in phase 1 trial
hVIVO supports Cidara Therapeutics' positive Phase 2b influenza study results
Valneva signs exclusive German vaccine distribution deal with CSL Seqirus